Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206102 · ClinicalTrials.gov registry record · Phase 4
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,098
- Enrollment target
NCT00206102 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 1,098 participants.
The verdict
NCT00206102, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,098 participants
- Enrollment target
Study Summary
This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone (RISPERDAL). This study is being conducted to fulfill the SEROQUEL Phase IV commitment regarding evaluation of cataractogenic potential.
Interventions
- DRUG risperidone
- DRUG quetiapine fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,098 participants |
| Start Date | 2003-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206102
The ClinicalTrials.gov registry entry for NCT00206102 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,098 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00206102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206102 about?
NCT00206102 is a clinical study titled "A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder". This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone (RISPERDAL). This study is being conducted to fulfill the SEROQUEL Phase IV ...
What is the current status of trial NCT00206102?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,098 participants. The study started on 2003-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00206102?
The interventions under investigation include: risperidone (DRUG), quetiapine fumarate (DRUG).
Who is sponsoring clinical trial NCT00206102?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.